Ceregene   Report issue

For profit Phase 1 Phase 2
Founded: San Diego CA United States (2000)
Status: Acquired by Sangamo BioSciences (2013)

Organization Overview

First Clinical Trial
2004
NCT00087789
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2009

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Ceregene (www.ceregene.com)

Active Ingredients

Drugs in Phase 2 Trials (1)

cere-120 (3 trials)

Drugs in Phase 1 Trials (1)

cere-110 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 1)

Parkinson Disease (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 2